Multi-Center Evaluation of an Advanced Extracellular Matrix Technology for the Management of Chronic Wounds – A Canadian Experience

Introduction

ECM® technology works as a scaffold to help rebuild missing or damaged tissue. Unlike traditional collagen dressings, ECM® is entirely natural, and is an accurate mimic of the scaffold found in healthy tissue. ECM® contains collagen, but also a range of other secondary molecules that are important for healing. Additionally, ECM® has been shown to modulate wound proteases. The aim of this case series was to clinically evaluate an advanced extracellular matrix (ECM®) technology across different Canadian care settings for the management of chronic wounds.

Methods

Thirty patients were recruited from three sites (see also population summary below). Wound types included DFUs, PUs, skin tears, pilonidal sinus, necrotizing fasciitis, venous leg ulcers, dehisced abdominal and traumatic wound. Wound management was undertaken across various care settings, including in-patient, out-patient and home health. All wounds were managed with best practice, including debridement, maintenance of a moist wound environment and appropriate compression and off-loading. All wounds were managed with an ECM®, applied every 2–7 days to the wound bed. Wounds were visually inspected, imaged and measured over the course of management with ECM®.

Results

Conclusions

This represents the first Canadian evaluation of ECM® for the management of wounds. Improvements to the granulation tissue were observed, and otherwise stalled chronic wounds began to resolve. Results to date are encouraging, and the availability of this advanced technology to Canadian wound specialists provides another tool for the management of these complex pathologies.

References and Disclosures


Financial support was provided by AstraZeneca Limited (New Zealand). The authors would like to acknowledge the assistance of Dr. Vinnie Neaves and Sandi Dempsey in data analysis and preparation of this report.